Development of a live, oral, attenuated vaccine against El Tor cholera
- PMID: 7995992
- DOI: 10.1093/infdis/170.6.1518
Development of a live, oral, attenuated vaccine against El Tor cholera
Abstract
Vibrio cholerae El Tor strains from Peru, Bangladesh, and Bahrain were attenuated by deletion of a genetic element that encodes virulence factors and RS1. The B subunit of ctx (ctxB) was reintroduced into the recA gene of the deletion mutants, rendering them unable to recombine with exogenous genetic elements and generating Peru-3, Bang-3, and Bah-3. Fifteen volunteers received one dose of various vaccine strains at 4 x 10(6) to 1 x 10(8) cfu. All strains colonized the gut. A > or = 4-fold rise in vibriocidal titer was observed in 14 volunteers, with titers of > or = 1600 in 13. Peru-3 was the least reactogenic, but 2 of 6 volunteers had loose stools. Peru-14, a filamentous motility-deficient mutant of Peru-3, was well tolerated and colonized 18 of 21 volunteers at doses of 2 x 10(6) to 1 x 10(9) cfu. Also, when 8 Peru-3 or Peru-5 vaccinees, 5 Peru-14 vaccinees, and 8 controls were challenged with 2 x 10(6) cfu V. cholerae El Tor Inaba (N16961), 11 vaccinees were protected compared with no controls. Peru-14 shows promise as a safe, effective, single-dose oral vaccine against El Tor cholera.
Similar articles
-
The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.Infect Immun. 2005 May;73(5):3018-24. doi: 10.1128/IAI.73.5.3018-3024.2005. Infect Immun. 2005. PMID: 15845509 Free PMC article. Clinical Trial.
-
Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.Infect Immun. 2002 Apr;70(4):1965-70. doi: 10.1128/IAI.70.4.1965-1970.2002. Infect Immun. 2002. PMID: 11895960 Free PMC article. Clinical Trial.
-
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.Infect Immun. 1999 Dec;67(12):6341-5. doi: 10.1128/IAI.67.12.6341-6345.1999. Infect Immun. 1999. PMID: 10569747 Free PMC article. Clinical Trial.
-
Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.Expert Rev Vaccines. 2009 Dec;8(12):1643-52. doi: 10.1586/erv.09.137. Expert Rev Vaccines. 2009. PMID: 19943759 Review.
-
PaxVax CVD 103-HgR single-dose live oral cholera vaccine.Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Expert Rev Vaccines. 2017. PMID: 28165831 Review.
Cited by
-
Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains.Infect Immun. 1997 Jun;65(6):2127-35. doi: 10.1128/iai.65.6.2127-2135.1997. Infect Immun. 1997. PMID: 9169742 Free PMC article.
-
A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.Biomedicines. 2022 Aug 22;10(8):2050. doi: 10.3390/biomedicines10082050. Biomedicines. 2022. PMID: 36009598 Free PMC article. Review.
-
In vivo covalent cross-linking of cellular actin by the Vibrio cholerae RTX toxin.EMBO J. 2000 Oct 16;19(20):5315-23. doi: 10.1093/emboj/19.20.5315. EMBO J. 2000. PMID: 11032799 Free PMC article.
-
Back to the future: studying cholera pathogenesis using infant rabbits.mBio. 2010 May 18;1(1):e00047-10. doi: 10.1128/mBio.00047-10. mBio. 2010. PMID: 20689747 Free PMC article.
-
A Strategy for the Rapid Development of a Safe Vibrio cholerae Candidate Vaccine Strain.Int J Mol Sci. 2021 Oct 28;22(21):11657. doi: 10.3390/ijms222111657. Int J Mol Sci. 2021. PMID: 34769085 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical